New Year, new focus for ChiroBlock
business of producing and marketing chiral compounds and will focus
exclusively on providing chiral research and synthesis services for
pharmaceutical and biotechnology clients.
The company can handle production quantities of milligram to kilogram scale on its own, and says it has partnerships in place for batches in the 100kg to tonne range.
According to the company, concentration on its most profitable businesses - synthesis routing and exclusive research compounds - will allow it to improve its competitiveness.
One early benefit from the refocusing of the business will be an increase in investment in synthesis equipment, staff and new software tools for project management and information processing.
The company's existing range of chiral compounds, which included beta amino acids and glycosyl donors, is being transferred to subcontractors.
Beta amino acids have a number of interesting pharmacological properties, and are already commercialised as antibiotics and in development as potential anticancer drugs.
ChiroBlock's fluorinated glycosyl donors are used to create chiral compounds with monosaccharide groups. There has been a lot of interest in the development of compounds conjugated to these groups, as cell surface carbohydrates play a central role in many normal and pathological recognition processes. Furthermore, glycoconjugates are responsible for intercellular communication and cell growth.
For more details of ChiroBlock's services visit the company's website or e-mail pbagnpg@puveboybpx.qr.
